Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, 111 Dade Road, Guangzhou, 510120, China.
The First Hospital of Yulin, The Second Affiliated Hospital, Yanan University, 93 Yuxi Da Dao Road, Yulin, 719000, China.
BMC Public Health. 2018 Jul 6;18(1):841. doi: 10.1186/s12889-018-5678-0.
Allergic rhinitis (AR) is a worldwide health problem. Allergen avoidance is strongly recommended for AR patients. Air purification can reduce concentrations of particles in indoor air, including those of allergens. Air purifiers have been recommended by clinicians for AR patients, but few studies have focused on the removal of airborne allergens from home environments. Such studies have been limited by a lack of blinding, small samples, or a failure to measure allergen levels, disease activity, or a combination of these factors. This study investigates the efficacy of a high-efficiency air purifier in reducing disease activity in the homes of AR patients sensitive to the allergens produced by Artemisia (mugwort) pollen.
This is a randomized, double-blind, clinical controlled trial that will test active and inactive versions of an air purifier (Atmosphere®; Amway China). Sixty AR patients sensitive to the allergens produced by Artemisia pollen will be assigned randomly to two groups of equal numbers. All patients will undergo a 4-week treatment period and a 4-week observation period. Evaluation will be conducted at baseline (day 0) and on days 7, 14, 21, 28, and 56. The primary outcome measure will be the difference in visual analog scale scores from baseline. Secondary outcomes will be changes from baseline in nasal symptoms, allergy symptom scores, responses to the Rhinoconjunctivitis Quality of Life Questionnaire, Epworth Sleepiness Scale scores, and tolerability scores for the air purifier. Side effects of treatment will be recorded.
Reducing exposure to allergens can reduce the risk of conditions such as AR. We hypothesise that AR patients sensitive to the allergens produced by Artemisia pollen will not suffer symptoms in a pollen-free environment. AR patients can remove pollen from their homes using air purifiers, decreasing the risk of symptoms. We expect that our study results will provide reliable evidence for determining the effects of air-purification therapy.
ChiCTR-INR-17012481 . (Retrospectively registered 26 August 2017).
变应性鼻炎（AR）是一个全球性的健康问题。强烈建议 AR 患者避免过敏原。空气净化可以降低室内空气中颗粒的浓度，包括过敏原。临床医生建议 AR 患者使用空气净化器，但很少有研究关注家庭环境中空气传播过敏原的去除。这些研究受到缺乏盲法、样本量小或未能测量过敏原水平、疾病活动度或这些因素的组合的限制。本研究调查了高效空气净化器在降低对蒿属花粉产生的过敏原敏感的 AR 患者家中疾病活动度的疗效。
这是一项随机、双盲、临床对照试验，将测试高效空气净化器（Amway China 的 Atmosphere®）的活性和非活性版本。将 60 名对蒿属花粉产生的过敏原敏感的 AR 患者随机分为两组，每组人数相等。所有患者将接受为期 4 周的治疗期和 4 周的观察期。评估将在基线（第 0 天）和第 7、14、21、28 和 56 天进行。主要结局指标是视觉模拟量表评分与基线的差异。次要结局指标是从基线开始的鼻部症状、过敏症状评分、 Rhinoconjunctivitis 生活质量问卷的反应、Epworth 嗜睡量表评分和空气净化器耐受性评分的变化。将记录治疗的副作用。
减少接触过敏原可以降低患 AR 等疾病的风险。我们假设对蒿属花粉产生的过敏原敏感的 AR 患者在无花粉环境中不会出现症状。AR 患者可以使用空气净化器从家中去除花粉，降低出现症状的风险。我们预计我们的研究结果将为确定空气净化治疗效果提供可靠的证据。
ChiCTR-INR-17012481。（2017 年 8 月 26 日回顾性注册）。
